Matinas BioPharma Holdings, Inc.
MTNB · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -65.6% | 9,560.6% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | 100% | -423.1% | -44,090.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -2,082.6% | -760.2% | -74,106.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -2,093.2% | -658.6% | -70,554.5% |
| EPS Diluted | -4.98 | -5.28 | -3 | -5.04 |
| % Growth | 5.7% | -76% | 40.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |